First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers Meeting Abstract
| Authors: | Kris, M. G.; Mok, T.; Ou, S. H. I.; Martins, R.; Kim, D. W.; Goldberg, Z.; Zhang, H.; Taylor, I.; Letrent, S. P.; Janne, P. A. |
| Abstract Title: | First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers |
| Meeting Title: | 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 30 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2012 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2012-05-20 |
| Language: | English |
| ACCESSION: | WOS:000318009804334 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2012.30.15_suppl.7530 |
| Notes: | Meeting Abstract: 7530 -- Source: Wos |
